Priming With Azacitidine Can Chemosensitize DLBCL Patients, Achieve Good Responses

A phase I study showed that azacitidine priming followed by standard chemotherapy could be an effective approach to resistance in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL).
Source: Cancer Network - Category: Cancer & Oncology Source Type: news